Pelago Bioscience

Executive Summary

Pelago Bioscience is a Swedish biotechnology company specializing in target engagement and proteomics services for the drug discovery industry. Founded in 2016 and headquartered in Solna, Sweden, the company has developed a proprietary CETSA® (Cellular Thermal Shift Assay) technology that enables direct validation of drug-target interactions in live cells and tissues. This platform supports clients across the drug development spectrum, from early target discovery to preclinical stages, providing critical insights into drug efficacy and selectivity. As a private, pre-clinical stage company, Pelago operates as a service provider to pharmaceutical and biotech firms, leveraging its unique assay capabilities to accelerate drug development programs. The company's focus on target engagement fills a key gap in drug discovery by offering direct cellular evidence of target binding, which can reduce late-stage attrition and improve success rates. With no disclosed funding or valuation, Pelago's growth is likely driven by service revenue and strategic partnerships. The company's CETSA technology is well-regarded in the industry, and its continued adoption could position Pelago as a leader in the target engagement service market.

Upcoming Catalysts (preview)

• Q3 2026Announcement of major pharmaceutical partnership60% success
• Q4 2026Expansion of CETSA platform into new therapeutic areas (e.g., oncology, neurology)70% success
• Q2 2026Publication of validation studies in peer-reviewed journals80% success